» Articles » PMID: 33511518

Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment

Overview
Publisher Springer
Specialty Cell Biology
Date 2021 Jan 29
PMID 33511518
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Currently, there are no specific and efficient vaccines or drugs for COVID-19, particularly in severe cases. A wide range of variations in the clinical symptoms of different patients attributed to genomic differences. Therefore, personalized treatments seem to play a critical role in improving these symptoms and even similar conditions. Prompted by the uncertainties in the area of COVID-19 therapies, we reviewed the published papers and concepts to gather and provide useful information to clinicians and researchers interested in personalized medicine and cell-based therapy. One novel aspect of this study focuses on the potential application of personalized medicine in treating severe cases of COVID-19. However, it is theoretical, as any real-world examples of the use of genuinely personalized medicine have not existed yet. Nevertheless, we know that stem cells, especially MSCs, have immune-modulatory effects and can be stored for future personalized medicine applications. This theory has been conjugated with some evidence that we review in the present study. Besides, we discuss the importance of personalized medicine and its possible aspects in COVID-19 treatment, then review the cell-based therapy studies for COVID-19 with a particular focus on stem cell-based therapies as a primary personalized tool medicine. However, the idea of cell-based therapy has not been accepted by several scientific communities due to some concerns of lack of satisfactory clinical studies; still, the MSCs and their clinical outcomes have been revealed the safety and potency of this therapeutic approach in several diseases, especially in the immune-mediated inflammatory diseases and some incurable diseases. Promising outcomes have resulted in that clinical studies are going to continue.

Citing Articles

Revolutionizing medicine: recent developments and future prospects in stem-cell therapy.

Hussen B, Hussen B, Taheri M, Yashooa R, Abdullah G, Abdullah S Int J Surg. 2024; 110(12):8002-8024.

PMID: 39497543 PMC: 11634165. DOI: 10.1097/JS9.0000000000002109.


Potential therapeutic effects and nano-based delivery systems of mesenchymal stem cells and their isolated exosomes to alleviate acute respiratory distress syndrome caused by COVID-19.

Ghiasi M, Zarandi P, Dayani A, Salimi A, Shokri E Regen Ther. 2024; 27:319-328.

PMID: 38650667 PMC: 11035022. DOI: 10.1016/j.reth.2024.03.015.


Intratracheal Administration of Stem Cell Membrane-Cloaked Naringin-Loaded Biomimetic Nanoparticles Promotes Resolution of Acute Lung Injury.

Jin H, Zhao Y, Yao Y, Fan S, Luo R, Shen X Antioxidants (Basel). 2024; 13(3).

PMID: 38539816 PMC: 10967347. DOI: 10.3390/antiox13030282.


Therapeutic Potential of Bioactive Compounds from Edible Mushrooms to Attenuate SARS-CoV-2 Infection and Some Complications of Coronavirus Disease (COVID-19).

Baruah P, Patra A, Barge S, Khan M, Mukherjee A J Fungi (Basel). 2023; 9(9).

PMID: 37755005 PMC: 10532592. DOI: 10.3390/jof9090897.


Biogenesis, Composition and Potential Therapeutic Applications of Mesenchymal Stem Cells Derived Exosomes in Various Diseases.

Yuan Y, Wang J, Zhang Y, Li L, Reza A, Gurunathan S Int J Nanomedicine. 2023; 18:3177-3210.

PMID: 37337578 PMC: 10276992. DOI: 10.2147/IJN.S407029.


References
1.
Shetty R, Murugeswari P, Chakrabarty K, Jayadev C, Matalia H, Ghosh A . Stem cell therapy in coronavirus disease 2019: current evidence and future potential. Cytotherapy. 2020; 23(6):471-482. PMC: 7649634. DOI: 10.1016/j.jcyt.2020.11.001. View

2.
Atluri S, Manchikanti L, Hirsch J . Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. Pain Physician. 2020; 23(2):E71-E83. View

3.
Liu M . A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. Vaccines (Basel). 2019; 7(2). PMC: 6631684. DOI: 10.3390/vaccines7020037. View

4.
Mansouri F, Heydarzadeh R, Yousefi S . The association of interferon-gamma, interleukin-4 and interleukin-17 single-nucleotide polymorphisms with susceptibility to tuberculosis. APMIS. 2018; 126(3):227-233. DOI: 10.1111/apm.12810. View

5.
Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View